Redeye updates its estimates for Ependion following the Q2 2024 report, which showed stronger sales but lower profitability. The near-term outlook remains uncertain, but the company is well-positioned for medium- to long-term success as the underlying markets recover. Ependion continues to invest significantly in new product development and strategic areas, while simultaneously maintaining good cost control.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/